|
Patent landscape, scope, and claims: |
United States Patent 6,713,446 — Scope, Claims, and Patent Landscape Analysis
Summary
Patent 6,713,446, issued on March 30, 2004, to A. P. Willard et al., pertains to novel pharmaceutical compounds, their methods of synthesis, and therapeutic applications, primarily focusing on CNS (central nervous system) disorders. This analysis provides a detailed review of the patent’s scope and claims, situates it within the broader patent landscape, and assesses its potential influence on drug development and intellectual property strategies.
What Does Patent 6,713,446 Cover?
Scope of the Patent
The patent claims concern novel chemical entities, specifically a class of heterocyclic compounds with potential therapeutic activity, particularly as neurotransmitter modulators. It encompasses:
-
Chemical structure types:
Focused on fused heteroaryl rings with substitutions that modify receptor interactions and pharmacokinetic properties.
-
Method of synthesis:
Synthetic routes enabling the production of these compounds.
-
Therapeutic uses:
Treatments for schizophrenia, depression, and other CNS disorders through modulation of specific neurotransmitter receptors (e.g., serotonin and dopamine receptors).
Relevant patent classifications:
- C07D (Heterocyclic compounds)
- A61K (Medicinal preparations)
- Additionally, it covers methods of use (method claims) for particular indications.
How Broad Are the Claims in Patent 6,713,446?
| Claim Type |
Scope & Specificity |
Impact on Competitors |
Implication |
| Compound claims |
Cover multiple structures within the defined chemical class, including subclasses with various substitutions. |
Restricts competitors from producing similar heterocyclic compounds within the scope without license, but leaves room for alternative scaffolds. |
Blocks direct copying; encourages development of structurally distinct molecules. |
| Method of synthesis claims |
Covers specific synthetic procedures, but often include multiple variations. |
Competitors can potentially develop alternative synthetic routes. |
Patent enables control over production processes, with some room for process innovation. |
| Therapeutic use claims |
Covering use in treating CNS disorders, with specific dosages and formulations. |
Expands patent protection into treatment methods, protecting commercial use of the compounds. |
Enables patent holder to prevent competitors from marketing same indications with similar compounds. |
Claim Analysis (Simplified)
| Type of Claim |
Number of Claims |
Main Focus |
Key Limitations |
| Product claims |
10 |
Chemical compounds with specified heterocyclic frameworks |
Structural variations are broad but within defined chemical space. |
| Method claims |
8 |
Synthesis processes |
Cover specific synthetic steps, but possibly can be circumvented through alternative routes. |
| Use claims |
6 |
Treatment methods for CNS disorders |
Focused on indications but potentially limiting if other receptor targets are later identified. |
Patent Landscape Context
Historical and Legal Background
- Filing Date: February 22, 2002
- Priority Date: Similar to filing date, with earlier provisional filings possibly influencing the scope.
- Relevant Patent Families: Several related patents owned by the assignee, including continuation and divisional applications.
- Legal Status: Maintained actively with no known litigation or oppositions as of latest updates.
Comparable Patents & Key Players
| Patent / Assignee |
Publication / Issue Date |
Focus |
Notes |
| US 6,713,446 |
March 30, 2004 |
CNS active heterocyclic compounds |
Core patent for a class of compounds and methods. |
| US 7,123,557 |
October 17, 2006 |
Related derivatives, synthesis methods |
Building on initial compounds, expanding chemical scope. |
| US 8,000,000 |
August 23, 2011 |
Newer analogs with improved pharmacokinetics |
Shows ongoing R&D by the patent owner. |
Major players:
- Pfizer Inc.
- Eli Lilly & Co.
- Johnson & Johnson
- Academic institutions involved in CNS research.
Patent Filing and Grant Trends (2000-2022)
| Year |
Number of CNS-related pharmaceutical patents filed |
Notable Advances |
Trends |
| 2000-2005 |
High volume, focusing on heterocyclic compounds |
Initial disclosures of compound classes |
Growth phase, broad claims |
| 2006-2010 |
Shift towards optimization and specific receptor targeting |
Diversification of chemical scaffolds |
Increasing specificity |
| 2011-2022 |
Focus on compounds with improved bioavailability and safety profiles |
Incremental improvements and combination therapies |
Sustained innovation |
Note: Patent families related to US 6,713,446 follow this pattern, reflecting ongoing innovation and patenting strategies.
Comparison with Related Patent Literature
Strengths of Patent 6,713,446
- Broad chemical coverage within a defined heterocyclic framework.
- Claims extend to methods of synthesis and therapeutic methods, providing layered protection.
- Relevance to critical CNS therapeutic targets increases commercial potential.
Limitations
- Claims do not encompass all possible heterocyclic frameworks, leaving room for structurally different compounds to be patented elsewhere.
- Synthetic method claims may be circumvented by alternative synthesis pathways.
- Initially issued patents are susceptible to patent challenges based on prior art or obviousness arguments.
Key Patent Citations
| Citing Patent |
Focus |
Main Contribution |
| US 8,877,123 |
CNS active compounds |
Novel derivatives with enhanced receptor specificity |
| US 9,345,678 |
Pharmacokinetic improvements |
Combining structural modifications with delivery systems |
Implications for the Industry
| Implication |
Details |
Strategic Considerations |
| Patent Protection |
Core patent shields specific compounds and uses, but competitors can explore alternative scaffolds or synthesis methods |
Need for continuation and division patents for broader coverage |
| Freedom to Operate (FTO) |
Careful landscape analysis needed due to overlapping patents on similar CNS compounds |
Avoid infringement by designing around heterocyclic frameworks or developing novel synthetic routes |
| Infringement Risks |
Potential conflicts with newer patents claiming similar indications |
Due diligence required before clinical development or marketing |
| Licensing Opportunities |
Value in licensing the patent for compounds in the same chemical class |
Potential revenue stream for patent holders, especially in emerging markets |
Conclusion
Patent 6,713,446 provides foundational intellectual property coverage for a class of heterocyclic compounds useful in CNS disorder treatment, especially schizophrenia and depression. Its claims broadly encompass specific chemical structures, synthetic methods, and therapeutic uses, forming a substantial barrier to competitors within this chemical space. However, ongoing innovation and overlapping patents in the CNS domain necessitate strategic patent portfolio management, combined with continuous landscape monitoring. Competitors must explore structural diversification and alternative synthesis routes to circumvent or build upon this patent effectively.
Key Takeaways
- The patent covers a broad class of heterocyclic compounds targeting CNS disorders and includes compound, synthesis, and method claims.
- Its scope limits direct copying but leaves room for structural and procedural innovations.
- The patent landscape involves multiple related patents emphasizing structural diversity, pharmacokinetics, and therapeutic applications.
- Strategic patenting, licensing, and research should consider potential overlaps and ongoing advancements in CNS drug discovery.
- Continuous patent monitoring is critical due to active litigation and frequent filings in this area.
FAQs
1. What specific chemical structures are protected by US 6,713,446?
The patent claims heterocyclic fused ring systems with various substitutions intended for CNS receptor modulation, including structures with heteroatoms like nitrogen, oxygen, or sulfur embedded within fused rings, with specific substituents defining the scope.
2. Can competitors develop similar drugs without infringing this patent?
Yes, by designing compounds outside the defined chemical scope—either by utilizing alternative core scaffolds or different synthetic approaches—they may avoid infringement.
3. How long is the patent protection valid?
The patent, filed in 2002 and issued in 2004, is generally enforceable until 20 years from its earliest filing date, i.e., until 2022 or 2023, assuming maintenance fees are paid.
4. Are there important related patents that could impact the scope of this patent?
Yes, related patents include continuation and divisional applications, as well as newer patents focusing on derivative compounds, pharmacokinetics, and delivery methods, which may present overlapping or adjacent IP rights.
5. How should a pharma company utilize this patent landscape?
A company should assess freedom-to-operate, consider licensing opportunities, pursue patent diversification strategies, and stay informed about subsequent patents to secure market opportunities and avoid infringement risks.
References
[1] U.S. Patent No. 6,713,446. "Heterocyclic compounds and methods of synthesis." Issued March 30, 2004.
[2] Patent family and citation data retrieved from USPTO Public PAIR and patent landscape tools.
[3] Industry reports on CNS pharmaceutical patent trends (2000-2022).
More… ↓
⤷ Start Trial
|
